{
  "docId": "019de071-94a0-75ef-b86b-e4894fa7dc1d",
  "docSlug": "8b4d61768a47893d5f24ee0f1f9ae717",
  "documentTitle": "argenx SE | Results Presentation Deck | 20 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 20,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Data shows Efgartigimod consistently outperforming Placebo in both cycles.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-94a0-75ef-b86b-e4894fa7dc1d/4",
  "deckHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d",
  "deckJsonHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d.json",
  "deckAnchorHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.7,
        "x": 0.15,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Bar chart showing Efgartigimod vs Placebo performance in Cycle 1 and Cycle 2",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "397ccd64-9e70-458e-b79b-5f76afee03ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.9
      },
      "kind": "legend",
      "text": "Efgartigimod (dark blue), Placebo (grey)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c493a1a2-d8fa-458b-ac31-86c406ecef3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Depth of MG-ADL Response Demonstrated Across First Two Treatment Cycles in ADAPT",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35f58158-4f02-4512-bdd8-99949280174d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.19,
        "y": 0.215
      },
      "kind": "title",
      "text": "MG-ADL Responders Who Achieved Minimal Symptom Expression (MG-ADL of 0 or 1)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa083d2e-ae3a-4bb8-a0e9-55fb159352d8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "885f2494-a846-4d31-a9c5-b1fe37dae06b",
      "evidence": "The slide compares performance in 'Cycle 1 and Cycle 2' for 'Efgartigimod' and 'Placebo'.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 4,
      "beatId": "9fe8841f-daa1-4a47-a2f9-a2e61182196b",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "What Could Be",
      "beatSlug": "sparkline-what-could-be-2",
      "evidence": "The before-after slide and KPI overview present the potential benefits of argenx SE's pipeline",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ecfed2d1-84f5-4f61-b7a6-1bfbe0816e8d",
      "evidence": "The before-after slide and KPI overview present the potential benefits of argenx SE's pipeline",
      "position": 0,
      "objective": "Highlight the benefits of argenx SE's pipeline",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}